Invention Grant
- Patent Title: Binding molecules binding PD-L1 and LAG-3
-
Application No.: US16311604Application Date: 2017-06-20
-
Publication No.: US11214620B2Publication Date: 2022-01-04
- Inventor: Jamie Campbell , Nikole Sandy , Mihriban Tuna , Francisca Wollerton Van Horck , Katy Louise Everett , Miguel Gaspar , Matthew Kraman , Katarzyna Kmiecik , Mustapha Faroudi , Natalie Fosh , Barbara Hebeis
- Applicant: F-STAR DELTA LIMITED
- Applicant Address: GB Cambridge
- Assignee: F-STAR DELTA LIMITED
- Current Assignee: F-STAR DELTA LIMITED
- Current Assignee Address: GB Cambridge
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/EP2017/065073 WO 20170620
- International Announcement: WO2017/220569 WO 20171228
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00 ; A61K39/395 ; A61K45/06 ; C07K16/44
Abstract:
The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
Public/Granted literature
- US20190256602A1 BINDING MOLECULES BINDING PD-L1 AND LAG-3 Public/Granted day:2019-08-22
Information query
